China Heparin Industry Report, 2014-2017
  • Oct.2014
  • Hard Copy
  • USD $2,300
  • Pages:88
  • Single User License
    (PDF Unprintable)       
  • USD $2,150
  • Code: QJC016
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,400
  • Hard Copy + Single User License
  • USD $2,500

As the world's major heparin API producer and exporter, China boasts enormous raw materials, which provides a strong support for the production of China’s heparin products. In 2013, the live pigs raised in China could manufacture 27.9 trillion units of heparin crude products. And in H1 2014, the live hogs in China may produce 14.09 trillion units of heparin crude products, up 5.6% on a year-on-year basis.

In 2011-2013, affected by the economic downturn in Europe and America, the global heparin preparations market continued to drop, with the sales volume of main heparin preparations brands virtually presenting decline, thus dragging down the exports of China’s heparin products. In 2013, China exported approximately 13.68 trillion units of heparin and its salts, falling 5.9% year on year, and the figure edged down 0.6% from a year earlier to around 9.32 trillion units in Jan.-Aug. 2014.

The major global heparin API suppliers, including Hepalink, Nanjing King-friend, Dongcheng Biochemicals, Qianhong Bio-pharma, and Changshan Biochemical Pharmaceutical, have been among the top 4 heparin exporters in China for many years, together accounting for over 60% of China’s total heparin exports. In response to the impact from international markets, enterprises are stepping up efforts to figure out the solutions, with Hepalink expanding its market share of heparin crude products via M&As overseas. By contrast, the enterprises like Qianhong Bio-pharma, Dongcheng Biochemicals, and Changshan Biochemical Pharmaceutical have accelerated the R&D into and production of low molecular weight heparin preparations. And Nanjing King-friend is aggressively seeking to expand capacity through IPO.

Although the leading heparin enterprises planned to increase capacity and improve the heparin industry chain a few years ago, yet quite a few heparin API projects that had been scheduled to go into operation in 2014 were delayed successively due to depressed market demand or improved technical standards, these projects including Dongcheng Biochemicals’ 32t/a Crude Heparin Sodium Project and Qianhong Bio-pharma’s Heparin API and Preparations Expansion Project.

In terms of the proposed/ongoing projects, however, it is projected that the heparin API in China will achieve an additional capacity of more than 20 trillion units by 2015, when China’s total capacity will exceed 30 trillion units, accounting for roughly 80% of the global demand.

Given that America's economy showed signs of recovery and the European economy did not continue to deteriorate, we foresee that the market size of the global heparin API and preparation market will bounce back in 2014-2017, when China’s heparin industry, heparin API in particular, will see an improved degree of prosperity, thus further releasing new capacity.

肝素 英文_副本.png

China Heparin Industry Report, 2014-2017 mainly deals with the followings:
20120114.gifGlobal heparin supply & demand, competitive landscape and forecast, etc.;
20120114.gifDevelopment, access barriers, supply & demand, competitive landscape, import & export, and development forecast, etc. of China heparin API industry;
20120114.gifDevelopment, supply & demand, competitive landscape and development forecast, etc. of China heparin preparations industry;
20120114.gifOperation, Heparin Business, development prospect, etc. of 7 heparin enterprises, including Hepalink, Nanjing King-friend, Qianhong Bio-pharma, Dongcheng Biochemicals, as well as Changshan Biochemical Pharmaceutical.

1. Overview of Heparin Industry
1.1 Definition and Classification
1.2 Industry Chain

2. Operating Environment of Heparin Industry in China
2.1 Access Barriers
2.1.1 Related Policies
2.1.2 Technical Requirements 
2.1.3 Capital Barrier
2.2 Global Market Supply & Demand
2.3 Global Market Competition
2.4 Global Market Forecast
3. Development of Heparin API Industry in China
3.1 Status quo 
3.2 Supply & Demand
3.3 Competitive Landscape
3.4 Import & Export
3.4.1 Export
3.4.2 Import
3.5 Prospect and Forecast

4. Development of Heparin Preparation Industry in China
4.1 Market Size
4.2 Low Molecular Heparin Preparation
4.2.1 Low Molecular Weight Heparin Calcium Preparation
4.2.2 Low Molecular Weight Heparin Sodium Preparation
4.3 Unfractionated Heparin Preparation
4.4 Prospect and Forecast

5. Key Heparin Enterprises in China
5.1 Hepalink
5.1.1 Profile
5.1.2 Operation
5.1.3 Revenue Structure
5.1.4 Gross Margin
5.1.5 R&D and Investment
5.1.6 Major Clients 
5.1.7 Heparin Business
5.1.8 Prospect and Forecast

5.2 Qianhong Bio-pharma
5.2.1 Profile
5.2.2 Operation
5.2.3 Revenue Structure
5.2.4 Gross Margin
5.2.5 R&D and Investment
5.2.6 Major Clients 
5.2.7 Heparin Business
5.2.8 Prospect and Forecast

5.3 Dongcheng Biochemicals
5.3.1 Profile
5.3.2 Operation
5.3.3 Revenue Structure
5.3.4 Gross Margin
5.3.5 R&D and Investment
5.3.6 Major Clients 
5.3.7 Heparin Business
5.3.8 Prospect and Forecast

5.4 Changshan Biochemical Pharmaceutical
5.4.1 Profile
5.4.2 Operation
5.4.3 Revenue Structure
5.4.4 Gross Margin
5.4.5 R&D and Investment
5.4.6 Major Clients 
5.4.7 Heparin Business
5.4.8 Prospect and Forecast

5.5 Tianjin Chase Sun Pharmaceutical
5.5.1 Profile
5.5.2 Operation
5.5.3 Revenue Structure
5.5.4 Gross Margin
5.5.5 R&D and Investment
5.5.6 Major Clients 
5.5.7 Heparin Business
5.5.8 Prospect and Forecast

5.6 Nanjing King-friend
5.6.1 Profile
5.6.2 Operation and Prospect

5.7 Wanbang Biopharmaceuticals
5.7.1 Profile
5.7.2 Development
5.7.3 Operation
5.7.4 Heparin Business
Application of Heparin
Performance Comparison between Low Molecular Weight Heparin Preparation and Unfractionated Heparin Preparation
Heparin Industry Chain
Standard Requirements of Heparin Sodium API and Heparin in China
Global Heparin Preparation Market Size and YoY Growth, 2006-2013
Global Heparin Preparations Market Size by Product, 2010-2013
Regional Distribution of Global Heparin Preparations Consumed, 2013
Global Heparin API Demand and YoY Growth, 2007-2013
Major Global Heparin Producers
Revenue of Major Global Heparin Preparation Brands, 2010-2014
Global Demand for Heparin API, 2014-2017E
Global Heparin Preparations Market Size, 2014-2017E
Gross Margin of Major Heparin API Producers in China, 2008-2014
Pig Slaughter Capacity and YoY Growth in China, 2006-2014
China’s Theoretical Capacity of Heparin Crude Products, 2008-2014
China’s Theoretical Capacity of Heparin Sodium API, 2008-2014
Capacity of Major Heparin API Manufacturers in China, as of Jun, 2014 
Export Volume and Export Value of Heparin and Its Salts in China, 2008-2014
Average Export Prices of China’s Heparin and Its Salts and YoY Growth, 2008-2014
Export Structure of China’s Heparin and Its Salts by Region, Jan.-Aug. 2014
Top 10 Export Destinations of China’s Heparin and Its Salts by Export Value, 2012-2014
China’s Major Heparin and Its Salts Exporters by Export Value, 2013
Import Volume, Import Value and Unit Price of Heparin and Its Salts in China, 2008-2014
Heparin Sodium API Projects Proposed/Under Construction in China as of Jun. 2014
Chinese Heparin Preparations Market Size and YoY Growth, 2007-2013
Market Share of Heparin Preparations in China by Product, 2013
Chinese Low Molecular Weight Heparin Preparation Market Size and YoY Growth, 2007-2013
Market Share of Low Molecular Weight Heparin Calcium in China, 2013
Bid-winning Price of Major Low Molecular Weight Heparin Calcium Enterprises in China, 2013
Market Share of Low Molecular Weight Heparin Sodium Preparations in China, 2013
Market Share of Enoxaparin Sodium Preparation in China, 2013
Bid-winning Price of Major Low Molecular Weight Heparin Sodium Enterprises in China, 2013
Major Heparin Sodium Preparation Enterprises in China and Their Selling Prices, 2009-2014
Chinese Heparin Preparation Market Size and YoY Growth, 2014-2017E  
Revenue and Profit of Hepalink, 2008-2014
Operating Revenue Structure of Hepalink by Region, 2008-2014
Revenue Breakdown of Hepalink by Region, 2008-2014
Operating Revenue Structure of Hepalink by Product, 2008-2014
Revenue Breakdown of Hepalink by Product, 2008-2014
Consolidated Gross Margin of Hepalink, 2008-2014
R&D Costs and % of Total Revenue of Hepalink, 2009-2014
Hepalink’s Revenue from Top 5 Clients and % of Total Revenue, 2008-2014
Assets, Revenue and Profit of Hepalink’s Major Subsidiaries, 2014H1
Output, Sales Volume and Inventory of Hepalink’s Heparin Sodium API, 2011-2013
Gross Margin of Hepalink’s Main Heparin Products, 2008-2014
Revenue and Net Income of Hepalink, 2014-2017E
Revenue and Profit of Qianhong Bio-pharma, 2008-2014
Operating Revenue Structure of Qianhong Bio-pharma by Region, 2008-2014
Revenue Breakdown of Qianhong Bio-pharma by Region, 2008-2014
Operating Revenue Structure of Qianhong Bio-pharma by Product, 2008-2013
Operating Revenue Structure of Qianhong Bio-pharma by Product, 2014H1
Revenue Breakdown of Qianhong Bio-pharma by Product, 2008-2013
Consolidated Gross Margin of Qianhong Bio-pharma, 2008-2014
R&D Costs and % of Total Revenue of Qianhong Bio-pharma, 2009-2014
Progress of Qianhong Bio-pharma’s Projects Proposed/Under Construction as of Jun. 2014
Qianhong Bio-pharma’s Revenue from Top 5 Clients and % of Total Revenue, 2009-2014
Assets, Revenue and Net Income of Qianhong Bio-pharma’s Subsidiaries, 2014H1
Gross Margin of Qianhong Bio-pharma’s Heparin Products, 2008-2013
Revenue and Net Income of Qianhong Bio-pharma, 2014-2017E
Assets, Revenue and Net Income of Dongcheng Biochemicals’ Subsidiaries, 2013
Revenue and Profit of Dongcheng Biochemicals, 2008-2014
Operating Revenue Structure of Dongcheng Biochemicals by Region, 2008-2014
Revenue Breakdown of Dongcheng Biochemicals by Region, 2008-2014
Operating Revenue Structure of Dongcheng Biochemicals by Product, 2008-2014
Revenue Breakdown of Dongcheng Biochemicals by Product, 2008-2014
Consolidated Gross Margin of Dongcheng Biochemicals, 2008-2014
Gross Margin of Dongcheng Biochemicals by Product, 2008-2014
Gross Margin of Dongcheng Biochemicals by Region, 2008-2014
R&D Costs and % of Total Revenue of Dongcheng Biochemicals, 2010-2014
Progress of Dongcheng Biochemicals’ Projects under Research by the End of 2013
Dongcheng Biochemicals’ Revenue from Top 5 Clients and % of Total Revenue, 2009-2014
Output, Sales Volume and Inventory of Dongcheng Biochemicals’ Heparin Sodium, 2011-2013
Revenue and Net Income of Dongcheng Biochemicals, 2014-2017E
Revenue and Profit of Changshan Biochemical, 2008-2014
Operating Revenue Structure of Changshan Biochemical Pharmaceutical by Region, 2008-2014
Revenue Breakdown of Changshan Biochemical Pharmaceutical by Region, 2008-2014
Operating Revenue Structure of Changshan Biochemical Pharmaceutical by Product, 2008-2014
Revenue Breakdown of Changshan Biochemical Pharmaceutical by Product, 2008-2014
Consolidated Gross Margin of Changshan Biochemical Pharmaceutical, 2008-2014
Gross Margin of Changshan Biochemical Pharmaceutical by Region, 2008-2014
Gross Margin of Changshan Biochemical Pharmaceutical by Product, 2008-2014
R&D Costs and % of Total Revenue of Changshan Biochemical Pharmaceutical, 2009-2014
Progress of Changshan Biochemical Pharmaceutical’s Products under Research as of Jun. 2014
Changshan Biochemical Pharmaceutical’s Revenue from Top 5 Clients and % of Total Revenue, 2009-2014
Output, Sales Volume and Inventory of Changshan Biochemical Pharmaceutical’s Heparin Sodium API and Its Preparations, 2011-2014
Revenue and Net Income of Changshan Biochemical Pharmaceutical, 2014-2017E
Revenue and Profit of Tianjin Chase Sun Pharmaceutical, 2008-2014
Output, Sales Volume and Inventory of Tianjin Chase Sun Pharmaceutical’s Finished Drug Products, 2011-2013
Operating Revenue Structure of Tianjin Chase Sun Pharmaceutical by Region, 2008-2014
Revenue Breakdown of Tianjin Chase Sun Pharmaceutical by Region, 2008-2013
Operating Revenue Structure of Tianjin Chase Sun Pharmaceutical by Product, 2008-2014
Revenue Breakdown of Tianjin Chase Sun Pharmaceutical by Product, 2008-2013
Consolidated Gross Margin of Tianjin Chase Sun Pharmaceutical, 2008-2014
Gross Margin of Tianjin Chase Sun Pharmaceutical by Region, 2008-2014
Gross Margin of Tianjin Chase Sun Pharmaceutical by Product, 2008-2014
R&D Costs and % of Total Revenue of Tianjin Chase Sun Pharmaceutical, 2008-2014
Tianjin Chase Sun Pharmaceutical’s Revenue from Top 5 Clients and % of Total Revenue, 2009-2014
Tianjin Chase Sun Pharmaceutical’s Revenue and Gross Margin from Heparin Business, 2008-2014
Revenue and Net Income of Tianjin Chase Sun Pharmaceutical, 2014-2017E
Existing and Fund-raised Heparin API and Preparation Capacities of Nanjing King-friend
Registered Capital of Wanbang Biopharmaceuticals, 2008-2014
Total Assets, Net Assets and Asset-liability Ratio of Wanbang Biopharmaceuticals, 2008-2014
Revenue, Operating Income and Gross Margin of Wanbang Biopharmaceuticals, 2012-2014
Net Income of Wanbang Biopharmaceuticals, 2008-2014

China Animal Vaccine Industry Report, 2019-2025

Chinese animal vaccine industry showed a CAGR of 8% between 2013 and 2017, but it was depressed by the outbreak of African Swine Fever in 2018 with the market size edging down 2.5% on an annualized ba...

China Blood Product Industry Report, 2020-2026

With the dynamic adjustment in the catalog of medicines covered by national medical insurance system, the scope of clinical use of almost all blood products grows tremendously, so does the reimburseme...

China Vacuum Blood Collection Device Industry Report, 2019-2025

As laboratory medicine advances, favorable polices are issued and people live a better life and care more about their health, vacuum blood collection systems get increasingly used. In 2018, global vac...

China Human Vaccine Industry Report, 2019-2025

China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseas...

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号